The present disclosure provides a method of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient discontinues posaconazole treatment, waits for at least 2 days, and is treated with a CYP3A4 substrate drug as soon as the treatment becomes safe. In some embodiments, treatment with the CYP3A4 substrate drug is postponed for approximately 2-42 days after discontinuation of posaconazole administration. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for approximately 2-42 days. [Selection diagram] Fig. 1
展开▼
